Literature DB >> 18161542

Practical Bayesian design and analysis for drug and device clinical trials.

Brian P Hobbs1, Bradley P Carlin.   

Abstract

Perhaps the most valuable contribution of Bayesian methods to health care evaluation involves study design. Drug and medical device clinical trialists are increasingly confronted with data that feature complex correlation structures, and are costly and difficult to obtain. In such settings, Bayesian trial designs are attractive since they can incorporate historical data or information from published literature, thus saving time and expense and minimizing the number of subjects exposed to an inferior treatment. Bayesian designs can also adapt to unexpected changes in the protocol, and allow the investigator to explore the plausibility of various outcome scenarios before any patients are enrolled in the trial. Recently, the FDA Center for Devices has encouraged hierarchical Bayesian statistical approaches which allow for the incorporation of such valuable historical data into the design and analysis of new device trials. The practical application of these methods has only become feasible in the last decade due to advances in computing via Markov chain Monte Carlo (MCMC) methods, especially as implemented in the popular BUGS software package. In this paper we illustrate Bayesian analysis and sample size calculations using BRugs, a function for calling BUGS from R. We provide illustrations in two applied settings where incorporation of available historical information is crucial, one concerning an AIDS drug trial and the other a comparison of left ventricular assist devices (LVADs).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18161542     DOI: 10.1080/10543400701668266

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  13 in total

1.  The Bayesian New Statistics: Hypothesis testing, estimation, meta-analysis, and power analysis from a Bayesian perspective.

Authors:  John K Kruschke; Torrin M Liddell
Journal:  Psychon Bull Rev       Date:  2018-02

2.  Neural dynamics differentially encode phrases and sentences during spoken language comprehension.

Authors:  Fan Bai; Antje S Meyer; Andrea E Martin
Journal:  PLoS Biol       Date:  2022-07-14       Impact factor: 9.593

3.  Interference patterns in subject-verb agreement and reflexives revisited: A large-sample study.

Authors:  Lena A Jäger; Daniela Mertzen; Julie A Van Dyke; Shravan Vasishth
Journal:  J Mem Lang       Date:  2019-12-10       Impact factor: 3.059

4.  Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.

Authors:  Swati Biswas; Diane D Liu; J Jack Lee; Donald A Berry
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

5.  No Impact of Stochastic Galvanic Vestibular Stimulation on Arterial Pressure and Heart Rate Variability in the Elderly Population.

Authors:  Akiyoshi Matsugi; Koji Nagino; Tomoyuki Shiozaki; Yohei Okada; Nobuhiko Mori; Junji Nakamura; Shinya Douchi; Kosuke Oku; Kiyoshi Nagano; Yoshiki Tamaru
Journal:  Front Hum Neurosci       Date:  2021-02-17       Impact factor: 3.169

6.  Bayesian model-averaged meta-analysis in medicine.

Authors:  František Bartoš; Quentin F Gronau; Bram Timmers; Willem M Otte; Alexander Ly; Eric-Jan Wagenmakers
Journal:  Stat Med       Date:  2021-10-27       Impact factor: 2.497

7.  A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results.

Authors:  Don van Ravenzwaaij; John P A Ioannidis
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

8.  Bayesian reanalysis of null results reported in medicine: Strong yet variable evidence for the absence of treatment effects.

Authors:  Rink Hoekstra; Rei Monden; Don van Ravenzwaaij; Eric-Jan Wagenmakers
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

9.  Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial.

Authors:  Samuel M Brown; Ithan D Peltan; Brandon Webb; Naresh Kumar; Nathan Starr; Colin Grissom; Whitney R Buckel; Raj Srivastava; Estelle S Harris; Lindsay M Leither; Stacy A Johnson; Robert Paine; Tom Greene
Journal:  Ann Am Thorac Soc       Date:  2020-08

10.  Analyses of drug combinations using missing data shortens trial periods in phase I/II oncology trials.

Authors:  Shinjo Yada; Chikuma Hamada
Journal:  Contemp Clin Trials Commun       Date:  2017-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.